Management Following Fracture

PQRI Data Collection	Sheet				
				/ /	☐ Male ☐ Female
Patient's Name	Practice Medical Record Nur	Practice Medical Record Number (MRN)			Gender
National Provider Identifier (NPI)				Date of Service	
Clinical Information	I			Billing Information	
Step 1 Is patient el	igible for this measure?				
		Yes	No	Code Required on Claim Form	
Patient is aged 50 years and older.				Verify date of birth on claim form.	
	ne hip, spine or distal radius Code for this visit OR there is			Refer to coding specifications document for list of applicable codes.	
If No is checked for any of the above, STOP. Do not report a CPT category II code.					
Step 2 Does patient meet or have an acceptable reason for not meeting the measure?					
Central Dual-energy X-ray Absorptiometry (DXA) Measurement OR Pharmacologic Therapy¹		Yes	No	Code to be Reported on Line 24D of Paper Claim Form, if <i>Yes</i> (or Service Line 24 of Electronic Claim Form)	
DXA ordered				3096F	
DXA performed				3095F	
Pharmacologic therapy prescribed ²				4005F	
Not ordered, performed of the following reasons: • Medical (eg, not indicate other medical reason)				3096F-1P OR 3095F-1P OR 4005-1P	
Patient (eg, patient de social, religious, other				3096F-2P OR 3095F-2P OR	4005F–2P
System (eg, resources to perform the services not available, other reason attributable to health care delivery system)				3096F-3P OR 3095F-3P OR 4005F-3P	
Document reason here and in medical chart.				If No is checked for all of the all 3096F–8P OR 3095F–8P OR (Central dual energy X-ray abs measurement was not ordered pharmacologic therapy for oster prescribed, reason not otherw	4005F-8P orptiometry [DXA] or performed and a eoporosis was not

Note: This measure should be reported at one of the following two instances if management following fracture has occurred or is planned within 3 months of fracture.

Prior DXA status or already on pharmacologic therapy pre-fracture meets this measure

¹⁾ During an office visit with ICD-9 diagnosis code for fracture of hip, spine or distal radius OR

²⁾ At the time of a procedure to repair a fracture



Management Following Fracture

continued from previous page

¹Pharmacologic Therapy: U.S. Food and Drug Administration approved pharmacologic options for osteoporosis prevention and/or treatment of postmenopausal osteoporosis include, in alphabetical order: bisphosphonates (alendronate, ibandronate, and risedronate), calcitonin, estrogens (estrogens and/or hormone therapy), parathyroid hormone [PTH (1-34), teriparatide], and selective estrogen receptor modules or SERMs (raloxifene).

²"Prescribed" includes patients who are currently receiving medication(s) that follow the treatment plan recommended at an encounter during the reporting period, even if the prescription for that medication was ordered prior to the encounter.